Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, July 1998, p. 1866-1867, Vol. 42, No. 7
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
LETTERS TO THE EDITOR
Inhibitory Effect of Erythromycin on Superoxide Anion Production
by Human Neutrophils Primed with Granulocyte-Colony Stimulating Factor
 |
LETTER |
We have recently demonstrated excessive neutrophil accumulation in
the airways of patients with diffuse panbronchiolitis (DPB) and have
also described therapeutic benefits of low-dose, long-term administration of erythromycin which are due to antiinflammatory rather
than bactericidal action (2, 4, 5, 8-10, 12). The
accumulation of neutrophils in the airway might contribute to lung
damage through the release of proteases, free oxygen radicals, and other degradative enzymes (1, 4, 7). In this
study, therefore, we attempted to elucidate whether erythromycin
has a direct inhibitory effect on superoxide anion production by
N-formyl-methionyl-leucyl-phenylalanine (FMLP)-stimulated human neutrophils primed with granulocyte
colony-stimulating factor (G-CSF).
Neutrophils were isolated from the blood of healthy volunteers with
mono-poly resolving medium (M-PRM; Flow Laboratories, Irvine, Scotland)
and density gradient centrifugation and were suspended in Hanks'
balanced salt solution (pH 7.4) (GIBCO, Grand Island, N.Y.) with 0.5%
human serum at 107 cells/ml. O2
generation by FMLP-stimulated neutrophils was measured by determining the superoxide dismutase-inhibitible reduction of cytochrome
c by a rapid microassay method (11). Neutrophils
were incubated with various concentrations of erythromycin for 30 min
at 37°C in a humidified atmosphere of 5% CO2 followed by
addition of the desired dose of G-CSF (Chugai Pharmaceuticals, Tokyo,
Japan) for 10 min. The cells were finally stimulated with
10
7 M FMLP for 10 min at 37°C, and then the absorbance
changes were measured at a wavelength of 550 nm with a Multiskan
instrument (Flow Laboratories, McLean, Va.). After each incubation,
cell viability was confirmed to be >95% by the trypan blue dye
exclusion method.
At concentrations of 10 and 50 ng/ml, G-CSF significantly primed the
O2
generation by human neutrophils (Fig. 1),
although G-CSF alone at 10 and 50 ng/ml induced no direct superoxide
production by human neutrophils during a 3-h incubation period (data
not shown). Erythromycin did not significantly affect
O2
generation by unprimed neutrophils at any
dose (Fig. 1). This confirmed previous observations that erythromycin
at the clinically relevant dose of 1 µg/ml (8) had no
direct inhibitory effect on unprimed neutrophils stimulated with FMLP
(3, 6) and also implies that the drug neither interferes
with binding of FMLP to its receptor on neutrophils nor acts as a free
radical scavenger. When neutrophils were only slightly primed by 5 ng of G-CSF/ml, only a 50-µg/ml concentration of the drug significantly inhibited FMLP-stimulated O2
generation
(P < 0.05). However, when human neutrophils were
significantly primed by 10 or 50 ng of G-CSF/ml prior to FMLP
stimulation to partly mimic the condition of the inflammatory site, the
clinically relevant dose of erythromycin markedly suppressed
O2
generation to the baseline levels observed
for unprimed neutrophils stimulated with FMLP (P < 0.01), as did the higher doses of 10 and 50 µg/ml (Fig. 1). This
result suggests that erythromycin acts to modulate the production of
neutrophil-derived oxygen radicals at the inflammatory site from an
excessive to a normal response rather than to suppress their
production, ultimately reducing epithelial injury in the airways of
patients with DPB.
More adequate experimental designs mimicking conditions found at the
inflammatory site are necessary to evaluate the possible beneficial
nonantibiotic effect of erythromycin.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 1.
Inhibitory effect of erythromycin on
O2 generation by unprimed or G-CSF-primed
human neutrophils stimulated with FMLP. Values are means (± standard
errors of the means) of absorbance at 550 nm for three independent
experiments. Statistical differences were determined by using the
Student t test, and data were considered statistically
significant when the P value was less than 0.05. Number
signs indicate statistical significance of differences in
O2 generation by primed versus unprimed
neutrophils in the absence of erythromycin (EM) (#, P < 0.01; ##, P < 0.05). Asterisks indicate statistical
significance of differences in O2 generation
by G-CSF-primed neutrophils in the presence versus the absence of
erythromycin at the indicated G-CSF concentrations (*,
P < 0.01; **, P < 0.05).
|
|
 |
REFERENCES |
| 1.
|
Cantin, A. M.,
S. L. North,
G. A. Fells,
R. C. Hubbard, and R. G. Crystal.
1987.
Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis.
J. Clin. Invest.
79:1665-1673.
|
| 2.
|
Fujii, T.,
J. Kadota,
K. Kawakami,
K. Iida,
R. Shirai,
M. Kaseda,
S. Kawamoto, and S. Kohno.
1995.
Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection.
Thorax
50:1246-1252[Abstract].
|
| 3.
|
Hojo, M.,
I. Fujita,
Y. Hamasaki,
M. Miyazaki, and S. Miyazaki.
1994.
Erythromycin does not directly affect neutrophil functions.
Chest
105:520-523[Abstract/Free Full Text].
|
| 4.
|
Ichikawa, Y.,
H. Ninomiya,
H. Koga,
M. Tanaka,
M. Kinoshita,
N. Tokunaga,
T. Yano, and K. Oizumi.
1992.
Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients.
Am. Rev. Respir. Dis.
146:196-203[Medline].
|
| 5.
|
Kadota, J.,
O. Sakito,
S. Kohno,
H. Sawa,
H. Mukae,
H. Oda,
K. Kawakami,
K. Fukushima,
K. Hiratani, and K. Hara.
1993.
A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis.
Am. Rev. Respir. Dis.
147:153-159[Medline].
|
| 6.
|
Mitsuyama, T.,
T. Tanaka,
K. Hidaka,
M. Abe, and N. Hara.
1995.
Inhibition by erythromycin of superoxide anion production by human polymorphonuclear leukocytes through the action of cyclic AMP-dependent protein kinase.
Respiration
62:269-273[Medline].
|
| 7.
|
Mohammad, J. R.,
B. S. Mohammad,
L. J. Pawluck,
D. M. Bucci,
N. R. Baker, and W. B. Davis.
1988.
Purification and cytotoxic potential of myeloperoxidase in cystic fibrosis sputum.
J. Lab. Clin. Med.
112:711-720[Medline].
|
| 8.
|
Nagai, H.,
H. Shishido,
R. Yoneda,
E. Yamaguchi,
A. Tamura, and A. Kurashima.
1991.
Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis.
Respiration
58:145-149[Medline].
|
| 9.
|
Oda, H.,
J. Kadota,
S. Kohno, and K. Hara.
1995.
Leukotriene B4 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis.
Chest
108:116-122[Abstract/Free Full Text].
|
| 10.
|
Oishi, K.,
F. Sonoda,
S. Kobayashi,
A. Iwagaki,
T. Nagatake,
K. Matsushima, and K. Matsumoto.
1994.
Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases.
Infect. Immun.
62:4145-4152[Abstract/Free Full Text].
|
| 11.
|
Pick, E., and D. Mizel.
1981.
Rapid microassays for the measurement of superoxide and hydrogen peroxide production by macrophage in culture using an automatic enzyme immunoassay reader.
J. Immunol. Methods
46:211-226[Medline].
|
| 12.
|
Sakito, O.,
J. Kadota,
S. Kohno,
K. Abe,
R. Shirai, and K. Hara.
1996.
Interleukin-1 , tumor necrosis factor and interleukin-8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy.
Respiration
63:42-48[Medline].
|
| | | | |
Jun-ichi Kadota
Tetsuji Iwashita
Yuichi Matsubara
Yuji Ishimatsu
Michiko Yoshinaga
Koh Abe
Shigeru Kohno
The Second Department of Internal Medicine Nagasaki University School of Medicine 1-7-1 Sakamoto, Nagasaki 852 Japan
|
Antimicrobial Agents and Chemotherapy, July 1998, p. 1866-1867, Vol. 42, No. 7
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Labro, M.-T.
(2000). Interference of Antibacterial Agents with Phagocyte Functions: Immunomodulation or ""Immuno-Fairy Tales""?. Clin. Microbiol. Rev.
13: 615-650
[Abstract]
[Full Text]
-
Vazifeh, D., Bryskier, A., Labro, M. T.
(2000). Effect of Proinflammatory Cytokines on the Interplay between Roxithromycin, HMR 3647, or HMR 3004 and Human Polymorphonuclear Neutrophils. Antimicrob. Agents Chemother.
44: 511-521
[Abstract]
[Full Text]